COMPANY:

Precede Bio

"Precede Biosciences...today announced the presentation of new data at the European Society for Medical Oncology (ESMO) Congress 2025"

"Precede Biosciences...today shared the company’s scientific presentations from the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting taking place from May 30 to June 3, 2025, in Chicago, Illinois."

"Precede Biosciences...oday shared the company’s scientific presentation from the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25 to 30, 2025, in Chicago, Illinois."

"Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field today....'Our study highlights the construction of an ER transcriptional dependency index with the potential to inform on who might benefit most from anti-endocrine therapy. Further work is required to validate this promising blood-based test and to confirm its utility in guiding therapeutic decisions.'"

"Precede Biosciences...today shared the company’s scientific poster presentation from the 2024 European Society for Medical Oncology (ESMO) annual meeting taking place from September 13 to 17, 2024 in Barcelona, Spain...These data highlight the ability for comprehensive epigenomic profiling to deliver a minimally invasive and clinically accessible surrogate of tumor PSMA expression in men with metastatic castration-resistant prostate cancer,"

"Precede Biosciences...today shared two scientific poster presentations from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois."

"Precede Biosciences...today shared two scientific poster presentations from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois...'Data presented at ASCO demonstrate the potential of Precede Bio’s blood-based approach to selecting patients for treatment with HER2-targeting therapies and next generation anti-endocrine therapies.'....'The data presented at ASCO highlight the potential of a novel blood-based epigenomic liquid biopsy platform to simultaneously predict ER status and infer activity of the ER signaling pathway in patients with metastatic breast cancer.'"

"Precede Biosciences...shared three scientific poster presentations from the 2024 American Association for Cancer Research (AACR) Annual Meeting....Precede Bio’s posters from AACR 2024 can be found in the presentations section of the company website and are linked directly below: Comprehensive epigenomic profiling from plasma to inform therapy selection: A proof-of-concept study in cancer; A novel epigenomic profiling assay reveals disease biology and therapeutic targets in gastro-esophageal cancer from 1mL of plasma; Novel liquid biopsy-based determination of lung cancer histology using a comprehensive epigenomic platform reveals enhancer activity as a key determinant for accurate classification."

"Precede Biosciences...announced three abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5 – 10 in San Diego, California."

"Precede Biosciences...announced that data from its platform were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX. The data demonstrate the ability of the platform to reveal disease-defining transcriptional biology of metastatic breast cancer and to accurately classify patients as HER2 3+ vs. HER2 0 and ER+ vs. ER- from just 1mL of plasma....Using Precede Biosciences' novel liquid biopsy technology, researchers profiled 130 metastatic breast cancer patients from the Dana-Farber Cancer Institute and three commercial biobanks. All patients had plasma drawn within six weeks of a tissue biopsy that was assessed for HER2 and ER by immunohistochemistry."

"Precede Biosciences...announces that data supporting the use of its platform to determine HER2 status in patients with metastatic breast cancer will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). The meeting will be held December 5-9 in San Antonio, TX....Data to be presented support the prospect of determining HER2 status from a simple blood draw and highlight a significant opportunity to advance the standard of care."

"Precede Biosciences...announced the first clinical data from its proprietary liquid biopsy platform were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, and simultaneously published in Nature Medicine. The data demonstrate the platform's unique capability to inform and impact clinical decisions by providing resolution into the activation status of individual disease-defining genes and pathways genome-wide, from a simple blood draw...a blood sample from a patient with advanced, progressive colorectal cancer (CRC) demonstrated an elevated signal at the HER2 gene promoter."